FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082664617> ?p ?o ?g. }

• W2082664617 endingPage "1762" @default.
• W2082664617 startingPage "1750" @default.
• W2082664617 abstract "The therapeutic landscape of non-small-cell lung cancer (NSCLC) has dramatically changed in the last few years with the introduction of molecularly targeted agents, leading to unprecedented results in lung tumors with a paradigmatic shift from a one size fits all approach to an histologic and molecular-based approach. The discovery of epidermal growth factor receptor (EGFR) mutations in NSCLC in 2004 and the marked response to the EGFR tyrosine kinase inhibitor gefitinib, in a small subset of patients harboring these genetic abnormalities, stimulated the study of other kinase mutants involvement in NSCLC. The incredible story of ALK rearranged tumors, with the rapid Food and Drug Administration approval of Crizotinib after only 4 years from the discovery of EML4-ALK translocation in NSCLC, has profoundly influenced the concept of drug development in NSCLC, paving the way to a novel series of molecularly selected studies with specific inhibitors. The identification of these oncogenic drivers has dramatically changed the genetic landscape of NSCLC moving away from the old concept of a large indistinct histological entity to a combination of rare clinically relevant molecular subsets. Recently, a renewed interest has been emerging on the human epidermal growth factor-2 (HER2) pathway. Genetic aberrations of this signaling pathway have been reported over time to be associated in NSCLC with different sensitivity to the EGFR tyrosine kinase inhibitors, to have a possible prognostic role and more recently HER2 amplification has been emerged as a possible mechanism in EGFR-mutated tumors of acquired resistance to the EGFR tyrosine kinase inhibitors. In addition, dysregulation of the HER2 pathway, in particular HER2 mutations (mostly, in-frame exon 20 insertions), may represent a possible novel therapeutic target in NSCLC, paving the way for a new generation of targeted agents in NSCLC. Since anecdotal case reports of clinical activity of anti-HER2 agents in NSCLC patients with HER2 mutations, several targeted agents have been evaluated in HER2-mutated patients, generating a growing interest upon this oncogenic driver, leading to the design of molecularly selected trials with anti-HER2 compounds and the rediscover of hastily thrown out drugs, such as neratinib. The aim of this article is to provide an overview of the role of HER2 dysregulation in NSCLCs, trying to throw a light not only on the strengths but also the weaknesses of the studies conducted so far. It is a long way to the clinical implementation of these biomarkers and probably the increasing use of next generation sequencing techniques, the creation of large multi-institutional molecular testing platforms and the design of rationally based trials can get closer personalized medicine in NSCLC." @default.
• W2082664617 created "2016-06-24" @default.
• W2082664617 creator A5001106275 @default.
• W2082664617 creator A5008894786 @default.
• W2082664617 creator A5010095820 @default.
• W2082664617 creator A5032066996 @default.
• W2082664617 creator A5049271920 @default.
• W2082664617 creator A5051002285 @default.
• W2082664617 creator A5054443196 @default.
• W2082664617 creator A5081361487 @default.
• W2082664617 date "2014-12-01" @default.
• W2082664617 modified "2023-10-16" @default.
• W2082664617 title "NSCLC and HER2: Between Lights and Shadows" @default.
• W2082664617 cites W1963541496 @default.
• W2082664617 cites W1964321121 @default.
• W2082664617 cites W1965073022 @default.
• W2082664617 cites W1967005016 @default.
• W2082664617 cites W1970232026 @default.
• W2082664617 cites W1974024530 @default.
• W2082664617 cites W1980497534 @default.
• W2082664617 cites W1987443121 @default.
• W2082664617 cites W1988142400 @default.
• W2082664617 cites W1988359324 @default.
• W2082664617 cites W1988679279 @default.
• W2082664617 cites W1990774346 @default.
• W2082664617 cites W1991341116 @default.
• W2082664617 cites W1993804787 @default.
• W2082664617 cites W1995242599 @default.
• W2082664617 cites W1995653405 @default.
• W2082664617 cites W1999828947 @default.
• W2082664617 cites W2001065504 @default.
• W2082664617 cites W2002602526 @default.
• W2082664617 cites W2003939995 @default.
• W2082664617 cites W2007010878 @default.
• W2082664617 cites W2007649418 @default.
• W2082664617 cites W2012915718 @default.
• W2082664617 cites W2014718912 @default.
• W2082664617 cites W2017600905 @default.
• W2082664617 cites W2018178643 @default.
• W2082664617 cites W2024772577 @default.
• W2082664617 cites W2026349049 @default.
• W2082664617 cites W2028837881 @default.
• W2082664617 cites W2029740942 @default.
• W2082664617 cites W2033588122 @default.
• W2082664617 cites W2037665548 @default.
• W2082664617 cites W2040565926 @default.
• W2082664617 cites W2041919461 @default.
• W2082664617 cites W2042378775 @default.
• W2082664617 cites W2043696829 @default.
• W2082664617 cites W2044186739 @default.
• W2082664617 cites W2046050735 @default.
• W2082664617 cites W2049449785 @default.
• W2082664617 cites W2055402151 @default.
• W2082664617 cites W2057180889 @default.
• W2082664617 cites W2061020371 @default.
• W2082664617 cites W2064977167 @default.
• W2082664617 cites W2065477010 @default.
• W2082664617 cites W2070533462 @default.
• W2082664617 cites W2074961178 @default.
• W2082664617 cites W2076209261 @default.
• W2082664617 cites W2079997250 @default.
• W2082664617 cites W2082592896 @default.
• W2082664617 cites W2084993196 @default.
• W2082664617 cites W2086156450 @default.
• W2082664617 cites W2087764235 @default.
• W2082664617 cites W2093273279 @default.
• W2082664617 cites W2093725835 @default.
• W2082664617 cites W2095659509 @default.
• W2082664617 cites W2098532770 @default.
• W2082664617 cites W2100439220 @default.
• W2082664617 cites W2101830631 @default.
• W2082664617 cites W2107002118 @default.
• W2082664617 cites W2107562400 @default.
• W2082664617 cites W2110841878 @default.
• W2082664617 cites W2111662961 @default.
• W2082664617 cites W2112854176 @default.
• W2082664617 cites W2113762115 @default.
• W2082664617 cites W2120840548 @default.
• W2082664617 cites W2121403704 @default.
• W2082664617 cites W2127518316 @default.
• W2082664617 cites W2130840817 @default.
• W2082664617 cites W2131510486 @default.
• W2082664617 cites W2133208325 @default.
• W2082664617 cites W2133867160 @default.
• W2082664617 cites W2133952555 @default.
• W2082664617 cites W2136028687 @default.
• W2082664617 cites W2137776025 @default.
• W2082664617 cites W2138297714 @default.
• W2082664617 cites W2141088968 @default.
• W2082664617 cites W2143913849 @default.
• W2082664617 cites W2144012034 @default.
• W2082664617 cites W2145640226 @default.
• W2082664617 cites W2149152398 @default.
• W2082664617 cites W2149971061 @default.
• W2082664617 cites W2150644635 @default.
• W2082664617 cites W2154149901 @default.
• W2082664617 cites W2155946891 @default.
• W2082664617 cites W2161821474 @default.

• next